Novo Nordisk is expanding the reach of semaglutide through new indications, seeking label expansions for Wegovy in cardiovascular disease and Ozempic in T2D patients with chronic kidney disease.

Novo Nordisk's Ozempic was first, but it was used off-label as a weight-loss drug, and had only initially been approved as a diabetes treatment and kidney disease treatment.

In a real-world setting, the administration of oral semaglutide leads to a significant reduction in the urinary ...

The 'Ladies First' rapper has partnered with Novo Nordisk to create more awareness around obesity and cardiovascular disease By Stephanie Sengwe Published on May 23, 2025 01:00PM EDT ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

Novo Nordisk is continuing to monitor trial participants to see how their liver disease progresses. The company anticipates new data in 2029. Nina Agrawal contributed reporting.

Novo Nordisk is trading at a premium to the industry, as seen in the chart below. Going by the price/earnings ratio, the company’s shares currently trade at 16.31 forward earnings, which is ...